Of the 883 cancers, 331 (37.5%) were luminal A-like, 148 (16.8%) luminal B-like, 199 (22.5%) HER2-positive, 134 (15.2%) TNBC, and in 71 (8.0%) cases the subtype could not be determined due to missing data on cancer Ki-67 expression. This evidence concerns the gene ERBB2 and cancer.